Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS OrphanPacific’s Orphan Drug Biz Faces Rough Going with Rising Costs
January 17, 2013
-
BUSINESS Domestic Drug Makers Working to Escape Dependence on Long-Listed Drugs through New Product Development
January 17, 2013
-
BUSINESS GMP Violations at Drug Substance Makers Prompt Series of New Voluntary Recalls of Generics; Stable Supplies Disrupted
January 16, 2013
-
ORGANIZATION JMA Vice Pres. Nakagawa Urges Pharmacies to Rigidly Check Medical Exam History of Epadel OTC Buyers
January 15, 2013
-
REGULATORY Focus May Be on Whether New Price Cutting Rule for Long-Listed Drugs Should Apply Only to Those Granted Premium
January 15, 2013
-
REGULATORY PMDA Probes How Insurance Pharmacies Utilize Drug Safety Information
January 11, 2013
-
BUSINESS Takeda to Pitch Lotriga for Patients with Residual Event Risks, Cultivate New Market
January 10, 2013
-
BUSINESS AbbVie to Focus on Specialty Care, “Not Interested” in Established Markets: CEO Winer
January 9, 2013
-
ORGANIZATION Efforts to Promote Generic Substitution Preferable to Cutting Prices of Long-Listed Drugs: Mr Sawai of JGA
January 8, 2013
-
BUSINESS “Appropriate Expressions” of Disease Awareness Ads Being Tested
January 7, 2013
-
ORGANIZATION Member Companies to Begin Enforcing New COP in FY2013: JPMA President Teshirogi
January 7, 2013
-
ORGANIZATION NHO to Review Calculation Method for Clinical Trial Costs
December 28, 2012
-
REGULATORY 2nd Abe Cabinet Inaugurated; Industry Awaits Decision on Perpetuation of Premium for New Drug Development
December 27, 2012
-
REGULATORY LDP to Finalize Tax Reform Outline for FY2013 by Late January
December 26, 2012
-
ORGANIZATION JMA to Discuss JPMA’s Transparency Guidelines with JPMA, Related Medical Organizations
December 25, 2012
-
REGULATORY MHLW to Establish a Venue for Discussions to Review Policies for OTC Switching of Lifestyle Disease Treatments
December 21, 2012
-
REGULATORY Osaka’s Healthcare Plan Highlights Differences in Definition of “Frequent Deliveries”
December 21, 2012
-
REGULATORY CSIMC Recommends New Rules on Reducing Prices of Long-Listed Drugs
December 21, 2012
-
REGULATORY MHLW to Revise and Consider Legislation of Ethical Guidelines for Clinical Research
December 20, 2012
-
REGULATORY Pharmaceutical Industry Welcomes Incoming Abe Administration
December 19, 2012
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…